<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, May 28, 2020 (HealthDay News) — The treatment effects of early comprehensive disease-modifying pharmacological therapy are considerable for patients with heart failure with reduced ejection fraction (HFrEF), according to a study published online May 21 in The Lancet<\/i>.<\/p>\n
Muthiah Vaduganathan, M.D., from Harvard Medical School in Boston, and colleagues estimated lifetime gains in event-free and overall survival with comprehensive therapy (angiotensin receptor-neprilysin inhibitors, \u03b2 blockers, mineralocorticoid receptor antagonists, and sodium\/glucose cotransporter 2 inhibitors) versus conventional therapy (angiotensin-converting enzyme inhibitor or angiotensin receptor blockers and \u03b2 blockers) in patients with chronic HFrEF. The treatment effects were estimated by making indirect comparisons of three pivotal trials.<\/p>\n
The researchers found that for the primary end point of cardiovascular death or hospital admission for heart failure, the hazard ratio for the imputed aggregate treatment effects of comprehensive disease-modifying therapy versus conventional therapy was 0.38. Hazard ratios were also favorable for cardiovascular death alone, hospital admission for heart failure alone, and all-cause mortality (hazard ratios, 0.50, 0.32, and 0.53, respectively). Compared with conventional therapy, treatment with comprehensive disease-modifying pharmacological therapy was estimated to afford 2.7 to 8.3 additional years free from cardiovascular death or first hospital admission for heart failure for an 80- and 55-year-old, respectively, and 1.4 to 6.3 additional years of survival, respectively.<\/p>\n
“The survival benefits estimated with comprehensive disease-modifying pharmacological therapy might be important in shared therapeutic decision making and future health system valuation,” the authors write.<\/p>\n
Several authors disclosed financial ties to the biopharmaceutical industry.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n